You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 48 No. 1, January 1991 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (385)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Valproatereatment of Acute Mania

A Placebo-Controlled

Harrison G. Pope, Jr, MD; Susan L. McElroy, l; E. Keck, Jr, MD; James I. Hudson, MD

Arch Gen Psychiatry. 1991;48(1):62-68.


Abstract



• We onducted a placeplacebo-controlled, double-blind valproate, iginally developed as an antiepileptic, patients with acute manic episodes who had previously failed to respond to or to tolerate lithium carbonate. Treatment duration was 7 to 21 days, with no other psychotropic medications permittedcept lorazepammg/d during the first 10 days of treatment. Serum valproateations were measured three times weekly; an unblindedator then adjusted dosage to produce serum concentrations between 50 and 100 mValproated superior to placebo in alleviating manic symptoms. The 17 patients randomized to active drug demonstrated a median 54% decrease in scores on the Young Mania Rating Scale as compared with a median 5.0%rease among the 19patients receiving placebo. On the 100-point Global Assessment Scale of overall psychiatric functioning, patients receiving vim-te proved by a median of 20 points as compared with a zero-point change with placebo. Significant differences also emerged on the Brief Psychiatric Rating Scale and in the number of supplemental doses of lorazepam by the patients in each group. Substantial antimanicappeared within 1 to 4 days of achieving therapeutic serum valproateations. Adverse effects were infrequent, with no adverse effect appearing significantly more frequently with valproateh placebo. We conclude that valproatets a useful new drug for the treatment of manic patients.



Author Affiliations



From the Biological Psychiatry Laboratory, Laboratories for Psychiatric Research, Psychotic Disorders Program, McLeantal, Belmont, Mass, and the Department of Psychiatry, Harvard Medical School, Boston, Mass.


Footnotes



Accepted for publication August 9, 1990.

Reprint requests to McLean McLean15 Mill St, Belmont, MA 02178 (Dr Pope).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study
Kessing et al.
Br. J. Psychiatry 2011;199:57-63.
ABSTRACT | FULL TEXT  

Efficacy of Sodium Valproate and Haloperidol in the Management of Acute Mania: A Randomized Open-Label Comparative Study
Sekhar et al.
J Clin Pharmacol 2010;50:688-692.
ABSTRACT | FULL TEXT  

Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial
Martin et al.
J Psychopharmacol 2009;23:814-825.
ABSTRACT  

Concomitant Use of Lorazepam With Tamoxifen in Bipolar Mania Clinical Trials--Reply
Yildiz et al.
Arch Gen Psychiatry 2009;66:108-109.
FULL TEXT  

Atypical antipsychotics in bipolar disorder: the treatment of mania
Cookson
Adv. Psychiatr. Treat. 2008;14:330-338.
ABSTRACT | FULL TEXT  

Protein Kinase C Inhibition in the Treatment of Mania: A Double-blind, Placebo-Controlled Trial of Tamoxifen
Yildiz et al.
Arch Gen Psychiatry 2008;65:255-263.
ABSTRACT | FULL TEXT  

Extended-Release Formulations in Epilepsy
Verrotti et al.
J Child Neurol 2007;22:419-426.
ABSTRACT  

Efficacy of Valproate Maintenance in Patients With Bipolar Disorder and Alcoholism: A Double-blind Placebo-Controlled Study
Salloum et al.
Arch Gen Psychiatry 2005;62:37-45.
ABSTRACT | FULL TEXT  

Australian and New Zealand Clinical Practice Guidelines for the Treatment of Bipolar Disorder
Royal Australian And New Zealand College Of Psychi
Aust N Z J Psychiatry 2004;38:280-305.
ABSTRACT | FULL TEXT  

Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression
Tohen et al.
Arch Gen Psychiatry 2003;60:1079-1088.
ABSTRACT | FULL TEXT  

National Depressive and Manic-Depressive Association Consensus Statement on the Use of Placebo in Clinical Trials of Mood Disorders
Charney et al.
Arch Gen Psychiatry 2002;59:262-270.
ABSTRACT | FULL TEXT  

Management of Psychiatric Disorders in Patients Infected with Human Immunodeficiency Virus
Mayer et al.
Clinical Infectious Diseases 2001;33:847-856.
ABSTRACT | FULL TEXT  

EDITORIAL: Polycystic Ovarian Syndrome--Relationship to Epilepsy and Antiepileptic Drug Therapy
Joffe et al.
J. Clin. Endocrinol. Metab. 2001;86:2946-2949.
FULL TEXT  

Efficacy of Olanzapine in Acute Bipolar Mania: A Double-blind, Placebo-Controlled Study
Tohen et al.
Arch Gen Psychiatry 2000;57:841-849.
ABSTRACT | FULL TEXT  

A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients With Bipolar I Disorder
Bowden et al.
Arch Gen Psychiatry 2000;57:481-489.
ABSTRACT | FULL TEXT  

Current Therapeutic Profile of Lithium
Gershon and Soares
Arch Gen Psychiatry 1997;54:16-20.
ABSTRACT  

Unanswered Questions, Unknown Future for One of Our Oldest Medications
Gitlin and Altshuler
Arch Gen Psychiatry 1997;54:21-23.
ABSTRACT  

The Use of Anticonvulsants in Psychiatry
Gaulin
Journal of Pharmacy Practice 1996;9:104-112.
ABSTRACT  

Efficacy of Divalproex vs Lithium and Placebo in the Treatment of Mania
Bowden et al.
JAMA 1994;271:918-924.
ABSTRACT  

Combining Lithium and Sodium Valproate for Bipolar Disorder
Mitchell et al.
Aust N Z J Psychiatry 1994;28:141-143.
ABSTRACT  

Sodium Valproate in the Treatment of Behavioral Disturbance in Dementia
Mellow et al.
J Geriatr Psychiatry Neurol 1993;6:205-209.
ABSTRACT  

Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes et al.
Arch Gen Psychiatry 1991;48:1082-1088.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.